This digital still from a narrated animated portrait depicts a woman overwhelmed by her body’s failure and by a health care system’s failure to care well.
AMA J Ethics. 2021;23(8):E658-659. doi:
10.1001/amajethics.2021.658.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Differentiating between best palliative care options and the curative and palliative potential of surgery is key to developing dual intentional clarity.
AMA J Ethics. 2021;23(10):E766-771. doi:
10.1001/amajethics.2021.766.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Leah M. Marcotte, MD, Jeffrey Krimmel-Morrison, MD, and Joshua M. Liao, MD, MSc
Individuals can underperform in circumstances of shared accountability. In clinical settings, this is an unintended consequence of the health care sector’s complexity fragmentation.
AMA J Ethics. 2020;22(9):E802-807. doi:
10.1001/amajethics.2020.802.
Graphic pathographies can illustrate how overreliance on statistics can obscure the clinical relevance of patients’ experiences of anxiety when they’re presented with prognoses.
AMA J Ethics. 2018;20(9):E897-901. doi:
10.1001/amajethics.2018.897.